Research programme: liver cell transplant therapy - Vesta Therapeutics

Drug Profile

Research programme: liver cell transplant therapy - Vesta Therapeutics

Alternative Names: Progenitor liver cell transplant therapy - Vesta Therapeutics

Latest Information Update: 26 Apr 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vesta Therapeutics
  • Developer Clinical Data; Vesta Therapeutics
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Liver disorders

Most Recent Events

  • 26 Apr 2012 No development reported - Preclinical for Liver disorders in USA (IV)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 25 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top